Loading...
XNAS
LUNG
Market cap82mUSD
Dec 05, Last price  
2.01USD
1D
-6.07%
1Q
15.52%
IPO
-95.20%
Name

Pulmonx Corp

Chart & Performance

D1W1MN
XNAS:LUNG chart
P/E
P/S
0.99
EPS
Div Yield, %
Shrs. gr., 5y
2.00%
Rev. gr., 5y
20.78%
Revenues
84m
+22.01%
20,004,00032,595,00032,733,00048,416,00053,662,00068,675,00083,789,000
Net income
-56m
L-7.31%
-18,479,000-20,703,000-32,231,000-48,661,000-58,923,000-60,843,000-56,394,000
CFO
-32m
L-16.15%
-18,394,000-20,765,000-30,633,000-41,388,000-45,083,000-37,610,000-31,537,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
IPO date
Oct 01, 2020
Employees
269
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT